Oberland Capital agreed to fund MeiraGTx with up to $400 million, according to the reported financing deal. The transaction is positioned as a vote of confidence in MeiraGTx’s late-stage gene therapy prospects and the commercialization potential of multiple assets. The report notes that one lead program recently returned to MeiraGTx after being reacquired from Johnson & Johnson, adding clarity to the company’s pipeline direction. Funding terms are expected to support development through clinical and toward regulatory steps. The MeiraGTx financing highlights how investors continue to prioritize gene therapy platforms when assets are nearing commercialization—particularly when ownership and program control become more streamlined.